Celcuity Inc (CELC) — Institutional Investor Activity (Q2 2026)

CELC ranks #2288 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CELC is a top-conviction position for Pfizer Inc — at 17.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CELC belongs to Baker Bros. Advisors LP, but the position matters far more to Pfizer Inc, who has 17.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Wealth Enhancement Advisory Services, LLC has trimmed its CELC position for two straight quarters, cutting it by $707.3K while still holding $1.1M.

CELC is down 6.2% today, but institutions show net buying of $1.1B this quarter — a divergence between today's price move and the underlying institutional flow.

CELC reported a net loss of $177.0M in its latest fiscal year.

• Not yet profitable — net loss of $177.0M in the latest fiscal year
• Net income declined year over year, from -$111.8M to -$177.0M
• Operating cash flow was negative, using $153.3M in cash
• Current ratio of 10.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 7625.06x equity — a highly leveraged balance sheet worth noting